Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are male and aged 18 or older
• People whose general health and ability to carry out daily activities meets a specific standard (called ECOG score 0 or 1 — confirm with trial site if unsure what this means)
• People with metastatic castration-resistant prostate cancer who have not yet received first-line treatment for this stage of the disease
• People who have previously received one new hormonal (endocrine) drug treatment during an earlier hormone-sensitive stage of prostate cancer
• People whose blood counts, liver function, kidney function, heart function, and heart rhythm all meet specific minimum levels, based on blood tests done without recent blood transfusions or growth factor injections in the 2 weeks before screening (confirm specific values with trial site)
• People whose partner is capable of having children must have had surgical sterilisation, or must agree to use contraception during the trial and after it ends
• People who are willing to sign a consent form and are expected to follow the study procedures reliably

Who may not be able to join:

• People who have previously received any PARP inhibitor treatment (such as Olaparib, Niraparib, Rucaparib, or similar drugs) for prostate cancer
• People who have participated in another clinical trial or had major surgery within the 4 weeks before joining this study
• People who have difficulty swallowing, ongoing chronic diarrhoea, bowel obstruction, or any other condition that could affect the ability to take or absorb oral medication
• People who have a history of epilepsy, or who have had a condition that can trigger seizures in the 12 months before joining — including mini-strokes (TIAs), stroke, or a serious head injury requiring hospitalisation
• People who have had active heart problems in the 6 months before joining, including severe or unstable chest pain, heart attack, significant heart failure, or dangerous heart rhythm problems caused by medication
• People with active hepatitis B or hepatitis C infection, based on specific blood test results (confirm details with trial site)
• People with a known allergy to the study drugs (Fluzopanib or Abiraterone nanocrystals) or any of their ingredients
• People with a history of a condition where the immune system does not work from birth, or who have had an organ transplant, or who are HIV-positive and meet certain additional conditions such as not being on effective HIV treatment, having recently changed HIV medication, or having low immune cell counts or recent serious infections (confirm specific details with trial site)
• People who have had another cancer diagnosed in the past 3 years, with some exceptions for certain slow-growing or fully resolved cancers (confirm with trial site)
• People who are sexually active with the ability to ejaculate and are unwilling to use the contraceptive measures required by the study throughout treatment and for 3 months after the last dose

Important: Always verify eligibility with the trial site directly before applying.